Brief: GRI Bio Inc Expects To Commence Phase 1A/B SLE Study In 1H 2024 With Topline Results Expected 2H 2024
07/08/2023 16:29
Aug 7 (Reuters) - GRI Bio Inc GRI.O :
* GRI BIO INC - COMPANY EXPECTS TO COMMENCE PHASE 1A/B SLE
STUDY
IN 1H 2024 WITH TOPLINE RESULTS EXPECTED 2H 2024
* GRI BIO INC - ANNOUNCED PRESENTATION OF PRECLINICAL DATA
FROM
ITS GRI-0803 DEVELOPMENT PROGRAM AT AUTOIMMUNITY CONFERENCE
Source text for Eikon: ID:nGNX6Xjdfk
Further company coverage: GRI.O
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027